{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:22:02Z","timestamp":1773674522827,"version":"3.50.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Cancer Council Western Australia Career Achievement"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment advances in metastatic breast cancer (MBC) have led to prolongation in overall survival (OS), nevertheless MBC is considered an incurable disease. Real-world data provides an opportunity to assess outcomes in an unselected patient population receiving standard-of-care therapy and assess for potential curability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Patient, tumor and treatment characteristics collected prospectively were analyzed. Univariate and multivariate analyses were performed for characteristics associated with OS \u226510-years. Time-to-next treatment (TTNT) and OS were compared to published clinical trials with significant survival benefits. Patients were deemed long-term survivors (LTS) if OS \u22655 or 10 years (TN or non-TN disease, respectively). Overall survival surpassing results in the recent ESME cohort analysis were deemed long-term responders (LTR). A stringent definition was used to define potentially cured patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Metastatic breast cancer patients (n\u2009=\u2009920) diagnosed between February 1999 and January 2021 were included. Overall survival \u226510 years was significantly more likely in those with de novo MBC, one anatomical metastatic site throughout the illness, HER2-positive disease, \u22643 metastatic sites at diagnosis, pathological concordance between primary\/metastatic tissue and clinical trial participation (all P\u2009&amp;lt;\u2009.001). Efficacy of first-line chemotherapy (n\u2009=\u2009452) or endocrine therapy (n\u2009=\u2009272) demonstrated similar or longer TTNT and\/or OS compared to published results for most regimens evaluated. LTS or LTR were seen in 16% of patients, with 8.7% potentially cured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Effective clinical trial outcomes can be achieved in a real-world setting. Overall survival \u226510-years and durable responses, with potential cure is possible. Real-world data provides valuable long-term outcome information and optimism for MBC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag039","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:38:22Z","timestamp":1770467902000},"source":"Crossref","is-referenced-by-count":0,"title":["Metastatic breast cancer outcome in a real-world setting: analysis for long-term survival and curability in a prospective dataset"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2135-2286","authenticated-orcid":false,"given":"Arlene","family":"Chan","sequence":"first","affiliation":[{"name":"Curtin University , Perth, WA 6102,","place":["Australia"]},{"name":"Breast Cancer Research Centre-WA , WA 6009,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengdie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Joondalup Health Campus, Ramsay Health Care , WA 6027,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mridula","family":"Arun","sequence":"additional","affiliation":[{"name":"Royal Perth Hospital , Perth, WA 6000,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Goddard","sequence":"additional","affiliation":[{"name":"Breast Cancer Research Centre-WA , WA 6009,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HuiJun","family":"Chih","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Health Sciences, Curtin University , Perth, WA 6102,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026031609555068300_oyag039-B1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Intl J Cancer"},{"key":"2026031609555068300_oyag039-B2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"2026031609555068300_oyag039-B3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2 a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026031609555068300_oyag039-B4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026031609555068300_oyag039-B5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026031609555068300_oyag039-B6","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"2026031609555068300_oyag039-B7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/CCI.21.00031","article-title":"Treatment and monitoring variability in US metastatic breast cancer care","volume":"5","author":"Caswell-Jin","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"2026031609555068300_oyag039-B8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1634\/theoncologist.2019-0699","article-title":"Comparative effectiveness of palliative chemotherapy in metastatic breast cancer: a real-world evidence analysis","volume":"25","author":"Feinberg","year":"2020","journal-title":"Oncologist"},{"key":"2026031609555068300_oyag039-B9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2026031609555068300_oyag039-B10","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s12325-022-02091-8","article-title":"Analysis of a real-world progression variable and related endpoints for patients with five different cancer types","volume":"39","author":"Torres","year":"2022","journal-title":"Adv Ther"},{"key":"2026031609555068300_oyag039-B11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann Oncol"},{"key":"2026031609555068300_oyag039-B12","doi-asserted-by":"publisher","first-page":"djx187","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026031609555068300_oyag039-B13","article-title":"Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: a real-world experience","volume":"16","author":"Labaki","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026031609555068300_oyag039-B14","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/s0959-8049(00)00325-7","article-title":"Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer","volume":"36","author":"Robain","year":"2000","journal-title":"Eur J Cancer"},{"key":"2026031609555068300_oyag039-B15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.clbc.2012.05.001","article-title":"Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival","volume":"12","author":"Gradishar","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"2026031609555068300_oyag039-B16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ctrv.2009.10.006","article-title":"Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis","volume":"36","author":"Mauri","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"2026031609555068300_oyag039-B17","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026031609555068300_oyag039-B18","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1200\/JCO.2001.19.6.1707","article-title":"Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III multicenter study","volume":"19","author":"Jassem","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026031609555068300_oyag039-B19","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","article-title":"Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer","volume":"29","author":"Stockler","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026031609555068300_oyag039-B20","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","article-title":"Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"26","author":"Albain","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026031609555068300_oyag039-B21","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"2026031609555068300_oyag039-B22","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","article-title":"Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026031609555068300_oyag039-B23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026031609555068300_oyag039-B24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2026031609555068300_oyag039-B25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.clbc.2011.06.003","article-title":"Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis","volume":"11","author":"Xu","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"2026031609555068300_oyag039-B26","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1200\/JCO.2015.61.5831","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study","volume":"33","author":"Ellis","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026031609555068300_oyag039-B27","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026031609555068300_oyag039-B28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"2026031609555068300_oyag039-B29","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026031609555068300_oyag039-B30","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"key":"2026031609555068300_oyag039-B31","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2026031609555068300_oyag039-B32","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"2026031609555068300_oyag039-B33","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026031609555068300_oyag039-B34","doi-asserted-by":"publisher","first-page":"100114","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008\u20132017 ESME cohort","volume":"6","author":"Grinda","year":"2021","journal-title":"ESMO Open"},{"key":"2026031609555068300_oyag039-B35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008\u20132016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026031609555068300_oyag039-B36","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"2026031609555068300_oyag039-B37","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable Her2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"2026031609555068300_oyag039-B38","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","article-title":"Survival differences among women with de novo stage IV and relapsed breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol"},{"key":"2026031609555068300_oyag039-B39","doi-asserted-by":"publisher","first-page":"102114","DOI":"10.1016\/j.ctrv.2020.102114","article-title":"Prognostic factors in patients with oligometastatic breast cancer - a systematic review","volume":"91","author":"van Ommen-Nijhof","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2026031609555068300_oyag039-B40","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s12282-021-01240-1","article-title":"Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report","volume":"28","author":"Nagasaki","year":"2021","journal-title":"Breast Cancer"},{"key":"2026031609555068300_oyag039-B41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10549-024-07431-6","article-title":"Receptor discordance in metastatic breast cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease","volume":"207","author":"Dowling","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2026031609555068300_oyag039-B42","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.2147\/CMAR.S369910","article-title":"Clinical characteristics, prognostic factors and treatment outcomes of patients with bone-only metastatic breast cancer","volume":"14","author":"Marie","year":"2022","journal-title":"Cancer Manag Res"},{"key":"2026031609555068300_oyag039-B43","doi-asserted-by":"publisher","first-page":"977226","DOI":"10.3389\/fonc.2022.977226","article-title":"Characteristics and survival in bone metastatic breast cancer patients with different hormone receptor status: a population-based cohort study","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"2026031609555068300_oyag039-B44","doi-asserted-by":"publisher","first-page":"1758835920987657","DOI":"10.1177\/1758835920987657","article-title":"Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program","volume":"13","author":"Bertho","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2026031609555068300_oyag039-B45","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1634\/theoncologist.2016-0067","article-title":"Biology and management of patients with triple-negative breast cancer","volume":"21","author":"Sharma","year":"2016","journal-title":"Oncologist"},{"key":"2026031609555068300_oyag039-B46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1634\/theoncologist.2018-0213","article-title":"Long-term survival of de novo stage IV human epidermal growth receptor 2 (HER2) positive breast cancers treated with HER2-Targeted therapy","volume":"24","author":"Wong","year":"2019","journal-title":"Oncologist"},{"key":"2026031609555068300_oyag039-B47","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s12282-012-0347-0","article-title":"Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review","volume":"19","author":"Kobayashi","year":"2012","journal-title":"Breast Cancer"},{"key":"2026031609555068300_oyag039-B48","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamaoncol.2021.6597","article-title":"Aiming at a tailored cure for ERBB2-Positive metastatic breast cancer","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026031609555068300_oyag039-B49","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.clbc.2019.01.014","article-title":"Features associated with long-term survival in metastatic breast cancer","volume":"19","author":"Klar","year":"2019","journal-title":". Clin Breast Cancer"},{"key":"2026031609555068300_oyag039-B50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000500298","article-title":"Long-term survival and cure in distant metastatic breast cancer","volume":"97","author":"G\u00fcth","year":"2019","journal-title":"Oncology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag039\/66921467\/oyag039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag039\/66921467\/oyag039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag039\/66921467\/oyag039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:55:59Z","timestamp":1773669359000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag039\/8487203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag039","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,16]]},"article-number":"oyag039"}}